Randomized phase II study of carboplatin plus irinotecan versus carboplatin plus amrubicin for extensive disease small cell lung cancer.

Trial Profile

Randomized phase II study of carboplatin plus irinotecan versus carboplatin plus amrubicin for extensive disease small cell lung cancer.

Completed
Phase of Trial: Phase II

Latest Information Update: 21 Apr 2017

At a glance

  • Drugs Amrubicin (Primary) ; Carboplatin (Primary) ; Irinotecan (Primary)
  • Indications Small cell lung cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 24 Mar 2013 Status changed from recruiting to active, no longer recruiting as reported by University Hospital Medical Information Network record (UMIN000008970).
    • 12 Oct 2012 New source identified and integrated (University Hospital Medical Information Network record UMIN000008970).
    • 24 Sep 2012 Status changed from not yet recruiting to recruiting according to the University Hospital Medical Information Network record (UMIN000008970).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top